Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are available for the treatment of chronic
myeloid leukemia in chronic phase (CML-CP), and several baseline and on-treatment …

Response to frontline BCR-ABL1-targeted tyrosine kinase inhibitor (TKI) therapy is
associated with an improved prognosis for patients with chronic myeloid leukemia (CML) …

Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …

Background Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem
cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for …

We explored the impact of early molecular response (EMR; BCR-ABL≤ 10% on the
international scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with newly …

Background: Tyrosine kinase inhibitors (TKI) improve survival in patients with chronic
myeloid leukemia in chronic phase (CML-CP), who meet molecular milestones at specific …

With the discovery of Philadelphia chromosome, understanding of chronic myeloid leukemia
(CML) pathobiology has tremendously increased. Development of tyrosine kinase inhibitors …

Abstract Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of one–two cases per 100,000 adults and accounts for∼ 15 …

The tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, and dasatinib are the standard of
care for treating patients with newly diagnosed chronic-phase chronic myeloid leukemia …

Simple Summary This review discusses the optimal selection of BCR-ABL1 tyrosine kinase
inhibitors (TKIs) as the first-line treatment for newly diagnosed chronic myelogenous …